Lates News

Novo Nordisk (NVO.US) fell nearly 4% to $70.87 before the market opened. On the news front, Novo Nordisk disclosed that the complete data from two Phase III clinical trials of its new weight loss drug CagriSema showed positive results in terms of weight loss and metabolic improvements, but the incidence of gastrointestinal side effects was higher than the placebo group. This result is basically consistent with the interim data previously announced but did not fully meet the market's expectations. Novo Nordisk previously announced details of a 68-week clinical study at the American Diabetes Association annual meeting in Chicago, showing that overweight or obese non-diabetic patients receiving CagriSema treatment had an average weight loss of about 23%, and overweight patients with type 2 diabetes had a weight loss of 15.8%.